AIM: To inform clinicians on the level of hepatotoxicrisk among antimycotics in the post-marketing setting,following the marketing suspension of oral ketocon-az
Hepatitis B virus(HBV) infection is a global public health problem,with an estimated 350 million people worldwide chronically infected and approximately 500000